Kerry J. Savage

Kerry J. Savage

600 West 10th Avenue
Vancouver, BC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 236 publications

Erratum: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Erratum: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 27, 2026

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 11, 2026

Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.

Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.

Journal: Haematologica

Published: March 06, 2026

LySeqST: a targeted sequencing assay for robust genomic classification of diffuse large B-cell lymphoma.

LySeqST: a targeted sequencing assay for robust genomic classification of diffuse large B-cell lymphoma.

Journal: Blood advances

Published: February 13, 2026

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Journal: Blood advances

Published: February 05, 2026

Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses.

Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses.

Journal: Blood advances

Published: February 05, 2026

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Journal: Blood cancer journal

Published: January 28, 2026

A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).

A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).

Journal: Blood neoplasia

Published: January 09, 2026

Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma.

Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma.

Journal: Future oncology (London, England)

Published: December 10, 2025

Bleomycin omission in limited-stage classic Hodgkin lymphoma with negative PET scan after two cycles of ABVD.

Bleomycin omission in limited-stage classic Hodgkin lymphoma with negative PET scan after two cycles of ABVD.

Journal: Haematologica

Published: October 17, 2025

Utility of the Central Nervous System International Prognostic Index in patients with primary mediastinal large B-cell lymphoma treated with rituximab-containing chemoimmunotherapy.

Utility of the Central Nervous System International Prognostic Index in patients with primary mediastinal large B-cell lymphoma treated with rituximab-containing chemoimmunotherapy.

Journal: Haematologica

Published: July 13, 2025

Retreatment with R-CHOP-like therapy in patients with late relapse of diffuse large B-cell lymphoma.

Retreatment with R-CHOP-like therapy in patients with late relapse of diffuse large B-cell lymphoma.

Journal: Blood advances

Published: June 30, 2025

Showing 1-12 of 236

Last Updated: 09/26/2026